Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 6 Wilms Tumor 2 Sarcoma, Ewing 2 Sarcoma 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Myeloproliferative Disorders 2 Myelodysplastic Syndromes 2 Medulloblastoma 2 Lymphoma, Non-Hodgkin 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Glioma 2 Ependymoma 2 Xanthogranuloma, Juvenile 1 Histiocytic Sarcoma 1 Cholangiocarcinoma 1 Central Nervous System Neoplasms 1 Biliary Tract Neoplasms 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

Gemcitabine 5 Cisplatin 5 Oxaliplatin 4 Magnetic Resonance Spectroscopy 4 Leucovorin 4 Fluorouracil 4 durvalumab 3 Taxes 3 futibatinib 2 fludarabine 2 Specimen Handling 2 Platinum 2 Paclitaxel 2 Nivolumab 2 Irinotecan 2 Folfox protocol 2 Fluorodeoxyglucose F18 2 Carboplatin 2 Biopsy 2 1,2-diaminocyclohexaneplatinum II citrate 2 zimberelimab 1 ulixertinib 1 tocilizumab 1 tivozanib 1 tislelizumab 1 regorafenib 1 pevonedistat 1 pembrolizumab 1 olutasidenib 1 olaparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Cholangiocarcinoma × ivosidenib × 30 days × Clear all

NCT07260175 2026-06-04

adIVO

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Recruiting

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡